Global Frontotemporal Disorders Treatment Market - 2020-2027
|額顳葉癡呆治療的全球市場：2020-2027 Global Frontotemporal Disorders Treatment Market - 2020-2027|
|出版日期: 按訂單生產||內容資訊: 英文||
The global frontotemporal disorders treatment market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Frontotemporal disorder, commonly known as Pick disease, is a form of dementia which is caused by a family of brain disorders known as frontotemporal lobar degeneration (FTLD). Frontotemporal dementia is a rare type of dementia which causes behaviour and language problems. Dementia is associated with disorders of mental abilities caused by some changes and damage in the brain and affects the front and sides of the brain. Dementia mostly affects people aged over 65 years, but frontotemporal dementia tends to start at a younger age. The common cases are diagnosed in people aged between 45-65 years, although it can also affect younger or older people. The mutation of different genes, such as VCP, CHMP2B, Tau gene, PGRN gene, FUS genes, TARDBP, and C9ORF72 gene are likely to cause frontotemporal disorders. Some of the common symptoms of frontotemporal disorders include dysarthria, perseveration, aphasia, utilization behaviour, social disinhibition, emotional changes, social-interpersonal changes, apraxia, gait disorder, dystonia, among others.
The diagnosis of frontotemporal disorders is mainly made through genetic tests, blood test, and physical examinations. These tests help to understand similar conditions, genetic mutation tests, and brain imaging changes in temporal and frontal lobes. Antipsychotics and antidepressants and antipsychotics medications can help in curing the symptoms of frontotemporal disorders. With increasing clinical trials and investment support from giant pharmaceutical companies to develop a treatment for this disorder is expected to drive the market growth during the forecast period.
The global frontotemporal disorders treatment market growth is majorly driven by certain factors such as the rising prevalence of dementia and other frontotemporal disorders, increasing drug development grants and funding by the government as well as non-government organizations.
Increasing prevalence of target disease and the growing geriatric population suffering from these disorders are expected to drive the market growth. As per the World Health Organization, about 50 Mn people have dementia, and there are around 10 Mn new cases annually, which is anticipated to boost the industry growth. Generally, the onset of this disorder occurs in the age range of 50 to 60 years and affected 50,000 to 60,000 Americans in 2011. Frontotemporal dementia accounts for 2-5% of the overall dementia cases. The prevalence of dementia is projected to be triple by 2050. As per the Dementia Statistics Organization, the number of people living with dementia are projected to increase by 204% from 50 million in 2018 to 152 million by 2050. The increasing number of dementia cases will further increase the cases of frontotemporal dementia, which is expected to drive more demand for frontotemporal disorders treatment drugs and medications.
Also, the rising government support and funding for research activities to find the treatment of target disease is expected to drive the growth of the market. Several organizations are involved in developing new medications, including the National Institute of Health (NIH), Alzheimer's Association, and National Institute on Aging. In 2019, the NIH spent around US$ 387 million on research projects for Alzheimer's Disease-Related Dementias (ADRD). These initiatives are expected to boost market growth over the forecast period. However, lack of awareness towards the target disease in a developing country may hamper the market growth.
On the basis of drug class, the global frontotemporal disorders treatment market is segmented into antipsychotics, cognitive enhancers, CNS stimulants, antidepressants, and others. Among these, the antidepressants are expected to show a lucrative opportunity over the forecast period. Antidepressant drugs are mainly used for the treatment of depressive disorders and other conditions, such as, dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, chronic pain, among others. Several other types of antidepressants are widely prescribed by physicians to manage patient health effectively. Also, (SSRIs) selective serotonin reuptake inhibitors also prove beneficial for the treatment of frontotemporal disorders. In October 2018, Lundbeck launched Brintellix tablets, which are used for the treatment of Major Depressive Disorder in India. Furthermore, in April 2019, Lupin launched antidepressant Fluoxetine tablets in the American market. The tablets are indicated for the treatment of the major depressive disorder, obsessive-compulsive disorder. Thus, owing to the rising number of the patient pool and recent product launches, the market is expected to witness high growth across the globe over the forecast period.
Based on indication, the market is classified into primary progressive aphasia (PPA), behavioural variant frontotemporal dementia, and motor decline. Among these, the behavioural variant frontotemporal dementia segment is anticipated to witness lucrative growth during the analysis period. The symptoms for behavioural variant frontotemporal dementia include apathy, disinhibition in interpersonal interactions, behavioural changes and progressive personality. Patients with such disorders are likely to see changes in stereotypic behaviour and dysexecutive symptoms that can severely affect an individual's health. Also, some patient may suffer from problems related to memory coupled with excessive emotions, will foster the overall segmental progress.
On the basis on distribution channel, the global frontotemporal disorders treatment is fragmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment is projected to account for the highest market share over the forecast period. Mostly the treatment of frontotemporal disorders in hospitals is done as in hospital settings; it is easier to manage an individual's health more accurately with the availability of skilled medical professionals. However, no specific treatments are available to cure the progression of frontotemporal diseases completely. So, doctors prescribe antidepressant medications that may help in treating anxiety and other symptoms.
North America region is dominating the global frontotemporal disorders treatment market accounting for the largest market share in 2019, owing to a large presence of advanced healthcare facilities and infrastructure in developed countries, such as the United States. Also, with the rising prevalence of frontotemporal disorders in this region is also driving the growth of the market. For instance, according to the National Institute of Neurological Disorders and Stroke, Alzheimer's disease alone, as one dementia disorder, affects over 5 million people in the United States. The toll on individuals, society, and caregivers is enormous and is expected to increase as the population ages. Frontotemporal dementia falls under rare diseases or orphan indications. In the United States, around 30,000 to 40,000 patients are suffering from frontotemporal disorders. Treatment of frontotemporal disorders falls under the Orphan Drug Act of 1983 as orphan drug indications are those which affect less than 200,000 people in the U.S. along with similar legislation in Europe. Orphan drug designation to FTD allows the continuation of clinical trials and development of a drug with commercial incentives, prioritizing consultation by FDA on clinical studies and reduction in regulatory fees.
The Asia-Pacific frontotemporal disorders market is expected to grow at the fastest CAGR over the forecast period due to the high prevalence of the target diseases due to the growing geriatric population base and increasing disposable income level.
The frontotemporal disorders treatment market is competitive and consists of several major players in the market. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Apotex Inc., Auro Pharma, Pfizer Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca plc., Mylan N.V., Sanofi S.A., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the frontotemporal disorders treatment market globally. For instance,
The global frontotemporal disorders treatment market report would provide an access to an approx. 61 market data table, 55 figures and 250 pages.
LIST NOT EXHAUSTIVE